Tyr60
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr60  -  POP4 (human)

Site Information
RkAVVLEyFtRHKRK   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 34668336

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 )
Disease tissue studied:
brain cancer ( 2 ) , glioblastoma ( 2 ) , glioma ( 2 )
Relevant cell line - cell type - tissue:
Jurkat (T lymphocyte) ( 1 ) , LN428_LNZ308 (glial) [EGFR (human), transfection, EGFR (wildtype)] ( 2 ) , LN428_LNZ308 (glial) [EGFR (human), transfection, EGFRvIII mutant (aka Delta EGFR, d2-7 EGFR; del. exon 2-7; in-frame loss 801 bp/267 aa in EC domain)] ( 2 ) , LN428_LNZ308 (glial) [EGFR (human), transfection, EGFRvIII-ki mutant (deletion of exons 2-7 plus kinase inactive mutation)] ( 2 )

References 

1

Mulhern D (2012) CST Curation Set: 13761; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

2

Chumbalkar V, et al. (2011) Analysis of Phosphotyrosine Signaling in Glioblastoma Identifies STAT5 as a Novel Downstream Target of ΔEGFR. J Proteome Res 10, 1343-52
21214269   Curated Info